John M. Taladay

John M. Taladay is Co-Chair of the Antitrust practice of Baker Botts. He is well-recognized as a leading global antitrust practitioner, known for his work in gaining merger approvals, defending criminal cartel investigations, litigating civil antitrust cases and managing complex international competition matters.

In working closely with the U.S. Federal Trade Commission, the U.S. Department of Justice Antitrust Division, the European Commission and other international agencies, Mr. Taladay has extensive experience in gaining merger clearances particularly in the technology, media, telecommunications, consumer products, software and pharmaceutical sectors and traditional industries including the automotive, airline, primary metals, agriculture, food, chemicals and electronics sectors.

Mr. Taladay has also led the defense of U.S. and foreign corporations and individuals in dozens of major cartel matters including antitrust grand jury investigations into allegations of price fixing, bid-rigging, market allocation and related offenses. He has navigated corporate clients through a range of cartel representation strategies from steadfast defense to leniency application to formal non-prosecution treatment. His litigation work includes acting as lead counsel in numerous civil antitrust class action and other litigation matters involving nearly all aspects of the antitrust laws.

Securing the Future of the U.S. Biopharmaceutical Industry: The Most-Favored-Nation Paradox

By Sujai Shivakumar and Anne Pritchett The Trump administration is pursuing lowering prescription drug costs primarily to end what it describes as “global freeloading” and to ensure U.S. patients pay prices comparable to those in other developed nations. The administration argues that while the United States represents less than 5 percent
Read More

Universities, Patents, and the Future of U.S. Competitiveness

By Shruti Sharma and Chris Borges Universities are among the most powerful engines of U.S. innovation, transforming federal research investments into scientific discoveries that underpin economic growth, technological leadership, and national security. Current law, via the Bayh-Dole Act, allows universities to patent inventions and license them to private companies, with royalties
Read More

How Counterfeit Drugs Threaten U.S. Health and Innovation

By Anne Pritchett According to the Department of Homeland Security, counterfeit drugs “threaten national security and public safety directly when introduced into government and critical infrastructure supply chains, and indirectly if used to generate revenue for transnational criminal organizations.” Furthermore, counterfeit drugs harm pharmaceutical innovation by eroding profitability and investor
Read More